Healthcare
Connect Biopharma Holdings Limited(CNTB)
Live Price
Offline$2.00
-3.85% today
1Y Change
+110.08%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $140.00M
- Revenue Growth
- -99.8%
- EPS Growth
- -257.1%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Connect Biopharma Holdings Limited (CNTB) is a Healthcare stock with a market cap of $140.00M and listed on NASDAQ. The stock last traded around $2.00 and up 110.1% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -99.8%, EPS growth of -257.1%, a dividend yield of 0.0%. What stands out right now is revenue -99.8%, EPS -257.1%, free cash flow -112.0% with operating margin -60312.5% and ROIC -67.7%. Valuation already assumes a fairly strong business story at price/sales 2908.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CNTB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-99.8% vs +7.6% peer median
Operating Margin
Below sector median
-60312.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -99.8% and EPS is at -257.1%, with operating margin around -60312.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | -0.4% | +5.5% | โ |
2026 Mar 31, 2026 | +10.0% | +3.8% | +0.4% | -3.4% |
2025 Aug 13, 2025 | -4.5% | -8.9% | -29.2% | -30.9% |
Benchmark Edge
CNTB vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CNTB
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CNTB Max Drawdown
-46.07%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CNTB and SPY.
Company Overview
Connect Biopharma Holdings Limited
NASDAQ
Connect Biopharma Holdings Ltd. is a global clinical-stage biopharmaceutical company focused on developing innovative therapies for T cell-driven inflammatory diseases. Headquartered in San Diego, California with operations in the United States and China, the company builds a pipeline of proprietary small molecules and antibodies using functional T cell assays to identify and validate therapeutic targets. Its lead product candidate, rademikibart, is an antibody targeting interleukin-4 receptor alpha currently in Phase 3 clinical development for atopic dermatitis and asthma. The company's second product candidate, icanbelimod, is an oral small molecule modulator of Sphingosine 1-Phosphate Receptor 1 in Phase 2 development for ulcerative colitis and Crohn's disease. Connect Biopharma aims to improve treatment outcomes for patients with chronic inflammatory conditions by leveraging advanced immunological research and targeted drug development strategies.
- Leadership
- Dr. Barry D. Quart Pharm.D.
- Employees
- 64
- Street Address
- 3580 Carmel Mountain Road, Suite 200
- Mailing
- San Diego, CA, 92130
- Region
- San Diego, CA, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2908.5
- Price/Book
- 3.3
Growth
- Revenue
- -99.8%
- EPS
- -257.1%
- Free Cash Flow
- -112.0%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -60312.5%
- Net Margin
- -58350.0%
- ROE
- -49.4%
- ROIC
- -67.7%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 3.74
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.